Watch OTLK. Know when insiders buy.
One email the day a filing lands. Free.
OTLK
Outlook Therapeutics, Inc.
0.66
−0.01 −0.91%
USD · close Sep 24
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $159.7MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$61.1MNET DEBT $955.8M52W 0.20 – 2.47SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Jun 30 | — | — | — | −$10.8M | −$20.3M | — | -0.15 | −$21M | — | — | Aug 18 |
| Q2 2026 · Mar 31 | — | — | — | −$14M | −$4.5M | — | -0.05 | −$7.8M | — | — | Aug 18 |
| Q1 2026 · Dec 31 | — | — | — | −$13.5M | −$23.1M | −232.7% | -0.38 | −$14.9M | — | — | Aug 18 |
| Q4 2025 · Sep 30derived | −$92K | — | 1098.5% | −$17.3M | −$13.3M | −333.6% | -0.19 | −$12.4M | — | — | Dec 19 |
| Q3 2025 · Jun 30 | $1.5M | — | 70.8% | −$15.7M | −$20.2M | −145.4% | -0.55 | −$11.9M | — | — | Aug 18 |
| Q2 2025 · Mar 31 | — | — | — | −$12.4M | −$46.4M | — | -1.50 | −$16.6M | — | — | Aug 18 |
| Q1 2025 · Dec 31 | — | — | — | −$21.6M | $17.4M | — | 0.72 | −$11M | — | — | Aug 18 |
| Q4 2024 · Sep 30derived | — | — | — | −$22.9M | $5.7M | — | 0.76 | −$17M | — | — | Dec 19 |
| Q3 2024 · Jun 30 | — | — | — | −$19.6M | $44.4M | — | -0.89 | −$19.5M | — | — | Aug 14 |
| Q2 2024 · Mar 31 | — | — | — | −$18.9M | −$114.3M | — | -8.01 | −$19.3M | — | — | Aug 14 |
| Q1 2024 · Dec 31 | — | — | — | −$10.3M | −$11.2M | — | -0.86 | −$13M | — | — | Aug 14 |
| Q4 2023 · Sep 30derived | — | — | — | −$12.5M | −$13M | — | -0.99 | −$12.7M | — | — | Dec 27 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Sep 30 | $1.4M | 4.0% | −$67.1M | −$62.4M | -4416.2% | -1.79 | −$51.8M | — | — | — | — |
| FY2024 · to Sep 30 | — | — | −$71.7M | −$75.4M | — | -4.06 | −$68.8M | — | — | — | — |
| FY2023 · to Sep 30 | — | — | −$53.1M | −$59M | — | -4.72 | −$43M | — | — | — | — |
| FY2022 · to Sep 30 | — | — | −$63.1M | −$66.1M | — | -0.31 | −$56.7M | — | — | — | — |
| FY2021 · to Sep 30 | — | — | −$51.7M | −$53.2M | — | -0.35 | −$54.3M | — | — | — | — |
| FY2020 · to Sep 30 | — | — | −$36.8M | −$35.2M | — | -0.67 | −$31.8M | — | — | — | — |
Every number comes from Outlook Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.